Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization.
Saved in:
| Title: | Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization. |
|---|---|
| Authors: | Konrath KM; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America., Liaw K; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Tursi NJ; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America., McCanna ME; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Warner BM; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.; Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.; Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, Canada., Gary EN; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Zhu X; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Livingston C; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Monastra C; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Frase D; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Chokkalingam N; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Huynh A; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Shupin N; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Bayruns K; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Kriete S; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Kim A; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Park J; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Vendramelli R; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Truong T; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Tierney K; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Azaransky K; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Moffat E; National Center for Foreign Animal Disease (NCFAD), Canadian Food Inspection Agency, Winnipeg, Canada., Embury-Hyatt C; National Center for Foreign Animal Disease (NCFAD), Canadian Food Inspection Agency, Winnipeg, Canada., Beer LA; Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Solanke O; Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Walker SN; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Kalia R; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, United States of America., Tang HY; Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Humeau LMPF; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, United States of America., Smith TRF; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, United States of America., Kobasa D; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Weiner DB; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America., Kulp DW; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America. |
| Source: | PLoS pathogens [PLoS Pathog] 2026 Feb 19; Vol. 22 (2), pp. e1013905. Date of Electronic Publication: 2026 Feb 19 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1553-7374 |
|---|---|
| DOI: | 10.1371/journal.ppat.1013905 |
